Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation

Jeffrey Cummings, Michael Gold, Mark Mintun, Michael Irizarry, Andrew von Eschenbach, Suzanne Hendrix, Donald Berry, Cristina Sampaio, Kaycee Sink, Jaren Landen, Miia Kivipelto, Michael Grundman, Steven E. Arnold, Allan Green, Katherine Partrick, Laura Nisenbaum, Aaron Burstein, Howard Fillit

Open source

DOI: 10.1016/j.tjpad.2024.100001
Published: 2025-01
Container: The Journal of Prevention of Alzheimer's Disease
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2024.100001,
  title = {Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation},
  author = {Jeffrey Cummings and Michael Gold and Mark Mintun and Michael Irizarry and Andrew von Eschenbach and Suzanne Hendrix and Donald Berry and Cristina Sampaio and Kaycee Sink and Jaren Landen and Miia Kivipelto and Michael Grundman and Steven E. Arnold and Allan Green and Katherine Partrick and Laura Nisenbaum and Aaron Burstein and Howard Fillit},
  year = {2025},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  doi = {10.1016/j.tjpad.2024.100001},
  url = {https://doi.org/10.1016/j.tjpad.2024.100001}
}

RIS

TY  - JOUR
TI  - Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation
AU  - Jeffrey Cummings
AU  - Michael Gold
AU  - Mark Mintun
AU  - Michael Irizarry
AU  - Andrew von Eschenbach
AU  - Suzanne Hendrix
AU  - Donald Berry
AU  - Cristina Sampaio
AU  - Kaycee Sink
AU  - Jaren Landen
AU  - Miia Kivipelto
AU  - Michael Grundman
AU  - Steven E. Arnold
AU  - Allan Green
AU  - Katherine Partrick
AU  - Laura Nisenbaum
AU  - Aaron Burstein
AU  - Howard Fillit
PY  - 2025
JO  - The Journal of Prevention of Alzheimer's Disease
DO  - 10.1016/j.tjpad.2024.100001
UR  - https://doi.org/10.1016/j.tjpad.2024.100001
ER  -

APA

Cummings, J., Gold, M., Mintun, M., Irizarry, M., Eschenbach, A. V., Hendrix, S., Berry, D., Sampaio, C., Sink, K., Landen, J., Kivipelto, M., Grundman, M., Arnold, S. E., Green, A., Partrick, K., Nisenbaum, L., Burstein, A., & Fillit, H. (2025). Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2024.100001

Source records

crossref · retrieved 2026-09-27T00:36:23.753Z